PL201688B1 - Zastosowanie hormonu przytarczyc - Google Patents

Zastosowanie hormonu przytarczyc

Info

Publication number: PL201688B1
Authority: PL; Poland
Prior art keywords: bone; pth; fractures; vertebral; stiffness
Prior art date: 1998-08-19

Application number

PL343595A

Other languages

English (en)

Polish (pl)

Other versions

PL343595A1 (en

Inventor

Janet M. Hock

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-08-19

Filing date

1999-08-19

Publication date

2009-04-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26792729&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL201688(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-08-19 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2001-08-27 Publication of PL343595A1 publication Critical patent/PL343595A1/xx

2009-04-30 Publication of PL201688B1 publication Critical patent/PL201688B1/pl

Links

210000000988 bone and bone Anatomy 0.000 title claims abstract description 107
238000000034 method Methods 0.000 title claims abstract description 12
108090000445 Parathyroid hormone Proteins 0.000 claims abstract description 105
239000000199 parathyroid hormone Substances 0.000 claims abstract description 28
102000003982 Parathyroid hormone Human genes 0.000 claims abstract description 27
208000001132 Osteoporosis Diseases 0.000 claims abstract description 26
229960001319 parathyroid hormone Drugs 0.000 claims abstract description 25
208000010392 Bone Fractures Diseases 0.000 claims abstract description 23
206010017076 Fracture Diseases 0.000 claims description 55
230000009467 reduction Effects 0.000 claims description 27
239000003814 drug Substances 0.000 claims description 18
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 10
150000001413 amino acids Chemical class 0.000 claims description 10
239000011575 calcium Substances 0.000 claims description 10
229910052791 calcium Inorganic materials 0.000 claims description 10
229930003316 Vitamin D Natural products 0.000 claims description 9
QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 9
235000019166 vitamin D Nutrition 0.000 claims description 9
239000011710 vitamin D Substances 0.000 claims description 9
150000003710 vitamin D derivatives Chemical class 0.000 claims description 9
229940046008 vitamin d Drugs 0.000 claims description 9
229940079593 drug Drugs 0.000 claims description 8
101001135770 Homo sapiens Parathyroid hormone Proteins 0.000 claims description 7
101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 claims description 7
102000058004 human PTH Human genes 0.000 claims description 7
239000003795 chemical substances by application Substances 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 6
230000000123 anti-resoprtive effect Effects 0.000 claims description 4
238000010254 subcutaneous injection Methods 0.000 claims description 4
239000007929 subcutaneous injection Substances 0.000 claims description 4
125000003275 alpha amino acid group Chemical group 0.000 claims 1
206010041569 spinal fracture Diseases 0.000 abstract description 39
208000014674 injury Diseases 0.000 abstract description 9
230000008733 trauma Effects 0.000 abstract description 4
102100036893 Parathyroid hormone Human genes 0.000 description 78
230000001054 cortical effect Effects 0.000 description 28
239000000902 placebo Substances 0.000 description 25
229940068196 placebo Drugs 0.000 description 25
210000001624 hip Anatomy 0.000 description 21
230000000694 effects Effects 0.000 description 20
238000011282 treatment Methods 0.000 description 19
239000000203 mixture Substances 0.000 description 15
239000000243 solution Substances 0.000 description 14
OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 description 12
210000000689 upper leg Anatomy 0.000 description 12
229910052500 inorganic mineral Inorganic materials 0.000 description 11
239000011707 mineral Substances 0.000 description 11
238000007634 remodeling Methods 0.000 description 11
210000004705 lumbosacral region Anatomy 0.000 description 8
238000002360 preparation method Methods 0.000 description 8
238000002560 therapeutic procedure Methods 0.000 description 7
210000000707 wrist Anatomy 0.000 description 7
241000282412 Homo Species 0.000 description 6
241001465754 Metazoa Species 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
230000009286 beneficial effect Effects 0.000 description 6
230000037118 bone strength Effects 0.000 description 6
229940011871 estrogen Drugs 0.000 description 6
239000000262 estrogen Substances 0.000 description 6
210000002758 humerus Anatomy 0.000 description 6
208000027418 Wounds and injury Diseases 0.000 description 5
230000006378 damage Effects 0.000 description 5
210000002683 foot Anatomy 0.000 description 5
229940088597 hormone Drugs 0.000 description 5
239000005556 hormone Substances 0.000 description 5
RLSSMJSEOOYNOY-UHFFFAOYSA-N m-methyl-PhOH Natural products CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 5
210000004197 pelvis Anatomy 0.000 description 5
239000003755 preservative agent Substances 0.000 description 5
210000003423 ankle Anatomy 0.000 description 4
230000037180 bone health Effects 0.000 description 4
210000002320 radius Anatomy 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
210000000614 rib Anatomy 0.000 description 4
239000003381 stabilizer Substances 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
206010065687 Bone loss Diseases 0.000 description 3
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
229930195725 Mannitol Natural products 0.000 description 3
241000283984 Rodentia Species 0.000 description 3
108010049264 Teriparatide Proteins 0.000 description 3
230000008901 benefit Effects 0.000 description 3
239000000872 buffer Substances 0.000 description 3
239000006172 buffering agent Substances 0.000 description 3
230000003139 buffering effect Effects 0.000 description 3
230000008859 change Effects 0.000 description 3
239000013078 crystal Substances 0.000 description 3
210000001981 hip bone Anatomy 0.000 description 3
230000006872 improvement Effects 0.000 description 3
239000000594 mannitol Substances 0.000 description 3
235000010355 mannitol Nutrition 0.000 description 3
239000000463 material Substances 0.000 description 3
230000011164 ossification Effects 0.000 description 3
238000007911 parenteral administration Methods 0.000 description 3
229920005862 polyol Polymers 0.000 description 3
150000003077 polyols Chemical class 0.000 description 3
230000009885 systemic effect Effects 0.000 description 3
230000000472 traumatic effect Effects 0.000 description 3
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
102000055006 Calcitonin Human genes 0.000 description 2
108060001064 Calcitonin Proteins 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
206010058359 Hypogonadism Diseases 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 2
150000001242 acetic acid derivatives Chemical class 0.000 description 2
230000009471 action Effects 0.000 description 2
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
230000001195 anabolic effect Effects 0.000 description 2
238000011444 antiresorptive therapy Methods 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000008416 bone turnover Effects 0.000 description 2
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
229960004015 calcitonin Drugs 0.000 description 2
229940069978 calcium supplement Drugs 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
210000002436 femur neck Anatomy 0.000 description 2
210000000245 forearm Anatomy 0.000 description 2
238000009472 formulation Methods 0.000 description 2
238000002657 hormone replacement therapy Methods 0.000 description 2
239000007788 liquid Substances 0.000 description 2
210000001672 ovary Anatomy 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
230000002335 preservative effect Effects 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
239000000047 product Substances 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
239000007787 solid Substances 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
229940095064 tartrate Drugs 0.000 description 2
229960005460 teriparatide Drugs 0.000 description 2
238000012360 testing method Methods 0.000 description 2
210000004291 uterus Anatomy 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 description 1
WPRAXAOJIODQJR-UHFFFAOYSA-N 1-(3,4-dimethylphenyl)ethanone Chemical compound CC(=O)C1=CC=C(C)C(C)=C1 WPRAXAOJIODQJR-UHFFFAOYSA-N 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
208000027502 Ankle fracture Diseases 0.000 description 1
201000004569 Blindness Diseases 0.000 description 1
208000020084 Bone disease Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
101001135732 Bos taurus Parathyroid hormone Proteins 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
ZAHDXEIQWWLQQL-IHRRRGAJSA-N Deoxypyridinoline Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(O)=C(C[C@H](N)C([O-])=O)C(CC[C@H](N)C(O)=O)=C1 ZAHDXEIQWWLQQL-IHRRRGAJSA-N 0.000 description 1
201000009273 Endometriosis Diseases 0.000 description 1
241000283070 Equus zebra Species 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
206010016970 Foot fracture Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
206010020462 Humerus fracture Diseases 0.000 description 1
206010020649 Hyperkeratosis Diseases 0.000 description 1
201000002980 Hyperparathyroidism Diseases 0.000 description 1
206010023204 Joint dislocation Diseases 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
208000006670 Multiple fractures Diseases 0.000 description 1
241000282339 Mustela Species 0.000 description 1
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
108010021717 Nafarelin Proteins 0.000 description 1
102100032256 Parathyroid hormone/parathyroid hormone-related peptide receptor Human genes 0.000 description 1
101710180613 Parathyroid hormone/parathyroid hormone-related peptide receptor Proteins 0.000 description 1
206010034156 Pathological fracture Diseases 0.000 description 1
241001494479 Pecora Species 0.000 description 1
208000006735 Periostitis Diseases 0.000 description 1
108010050808 Procollagen Proteins 0.000 description 1
241000700159 Rattus Species 0.000 description 1
208000027790 Rib fracture Diseases 0.000 description 1
206010061363 Skeletal injury Diseases 0.000 description 1
101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000000556 agonist Substances 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
239000003263 anabolic agent Substances 0.000 description 1
229940124325 anabolic agent Drugs 0.000 description 1
238000010171 animal model Methods 0.000 description 1
229940125681 anticonvulsant agent Drugs 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
229960000686 benzalkonium chloride Drugs 0.000 description 1
229960003872 benzethonium Drugs 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
239000000090 biomarker Substances 0.000 description 1
238000007470 bone biopsy Methods 0.000 description 1
230000037182 bone density Effects 0.000 description 1
239000002617 bone density conservation agent Substances 0.000 description 1
230000008468 bone growth Effects 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
230000018678 bone mineralization Effects 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
-1 carbohydrate alcohols Chemical class 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
108010049937 collagen type I trimeric cross-linked peptide Proteins 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
150000001896 cresols Chemical class 0.000 description 1
230000001351 cycling effect Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000000378 dietary effect Effects 0.000 description 1
SIYLLGKDQZGJHK-UHFFFAOYSA-N dimethyl-(phenylmethyl)-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethyl]ammonium Chemical compound C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 SIYLLGKDQZGJHK-UHFFFAOYSA-N 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
238000011049 filling Methods 0.000 description 1
150000004673 fluoride salts Chemical class 0.000 description 1
239000012634 fragment Substances 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
230000002710 gonadal effect Effects 0.000 description 1
210000002411 hand bone Anatomy 0.000 description 1
210000001564 haversian system Anatomy 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
238000009802 hysterectomy Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
229960000367 inositol Drugs 0.000 description 1
210000001503 joint Anatomy 0.000 description 1
210000001930 leg bone Anatomy 0.000 description 1
210000003041 ligament Anatomy 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
229960001078 lithium Drugs 0.000 description 1
208000018769 loss of vision Diseases 0.000 description 1
231100000864 loss of vision Toxicity 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
125000003717 m-cresyl group Chemical group [H]C1=C([H])C(O*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
230000035800 maturation Effects 0.000 description 1
238000002483 medication Methods 0.000 description 1
230000009245 menopause Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
FSBTYDWUUWLHBD-UDXTWCDOSA-N nafarelin acetate hydrate Chemical compound O.CC(O)=O.C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 FSBTYDWUUWLHBD-UDXTWCDOSA-N 0.000 description 1
230000000399 orthopedic effect Effects 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N p-hydroxybenzoic acid propyl ester Natural products CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
210000002990 parathyroid gland Anatomy 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
230000008447 perception Effects 0.000 description 1
210000003460 periosteum Anatomy 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
229960003742 phenol Drugs 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
102220240796 rs553605556 Human genes 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
230000000391 smoking effect Effects 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
150000005846 sugar alcohols Polymers 0.000 description 1
239000013589 supplement Substances 0.000 description 1
230000000153 supplemental effect Effects 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
229940086546 synarel Drugs 0.000 description 1
229940037128 systemic glucocorticoids Drugs 0.000 description 1
150000003892 tartrate salts Chemical class 0.000 description 1
210000002435 tendon Anatomy 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000008719 thickening Effects 0.000 description 1
210000001694 thigh bone Anatomy 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229940033663 thimerosal Drugs 0.000 description 1
210000000115 thoracic cavity Anatomy 0.000 description 1
229940034208 thyroxine Drugs 0.000 description 1
XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
230000004393 visual impairment Effects 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Endocrinology (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Orthopedics, Nursing, And Contraception (AREA)
Steroid Compounds (AREA)
Materials For Medical Uses (AREA)

PL343595A 1998-08-19 1999-08-19 Zastosowanie hormonu przytarczyc PL201688B1 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US9715198P	1998-08-19	1998-08-19
US9974698P	1998-09-10	1998-09-10

Publications (2)

Publication Number	Publication Date
PL343595A1 PL343595A1 (en)	2001-08-27
PL201688B1 true PL201688B1 (pl)	2009-04-30

Family

ID=26792729

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL343595A PL201688B1 (pl)	1998-08-19	1999-08-19	Zastosowanie hormonu przytarczyc

Country Status (33)

Country	Link
US (2)	US6977077B1 (ru)
EP (3)	EP2266598B1 (ru)
JP (5)	JP2002523375A (ru)
KR (1)	KR100454207B1 (ru)
CN (1)	CN1205997C (ru)
AR (1)	AR033639A1 (ru)
AT (1)	ATE231000T1 (ru)
AU (1)	AU746277B2 (ru)
BR (1)	BR9909445A (ru)
CA (1)	CA2325371C (ru)
CO (1)	CO5130020A1 (ru)
CY (2)	CY1113343T1 (ru)
CZ (1)	CZ301017B6 (ru)
DE (2)	DE15152726T1 (ru)
DK (4)	DK1769804T3 (ru)
DZ (1)	DZ2873A1 (ru)
EA (1)	EA003362B1 (ru)
ES (4)	ES2621653T3 (ru)
HK (3)	HK1030545A1 (ru)
HR (1)	HRP20000755A2 (ru)
HU (2)	HU1200430D0 (ru)
ID (1)	ID29039A (ru)
IL (2)	IL138829A0 (ru)
MY (1)	MY129227A (ru)
NO (2)	NO323984B1 (ru)
NZ (1)	NZ507056A (ru)
PE (1)	PE20001089A1 (ru)
PL (1)	PL201688B1 (ru)
PT (4)	PT2907522T (ru)
TR (1)	TR200003455T2 (ru)
TW (1)	TW576747B (ru)
UA (1)	UA72205C2 (ru)
WO (1)	WO2000010596A1 (ru)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6770623B1 (en) *	1997-12-09	2004-08-03	Eli Lilly And Company	Stabilized teriparatide solutions
US20040033950A1 (en) *	2000-09-26	2004-02-19	Hock Janet M.	Method of increasing bone toughness and stiffness and reducing fractures
DZ2873A1 (fr) *	1998-08-19	2003-12-15	Lilly Co Eli	Procédé pour augmenter la dureté et la rigidité osseuse.
AU7362900A (en) *	1999-09-20	2001-04-24	Eli Lilly And Company	Method for monitoring treatment with a parathyroid hormone
US7247609B2 (en)	2001-12-18	2007-07-24	Universitat Zurich	Growth factor modified protein matrices for tissue engineering
US7015195B2 (en)	2002-01-10	2006-03-21	Osteotrophin, Llc	Treatment of bone disorders with skeletal anabolic drugs
US8088734B2 (en)	2003-01-21	2012-01-03	Unigene Laboratories Inc.	Oral delivery of peptides
JP2007505883A (ja) *	2003-09-19	2007-03-15	ファイザー・プロダクツ・インク	２−アルキリデン−１９−ノル−ビタミンｄ誘導体及び副甲状腺ホルモンの組合せを含んでなる医薬組成物及び方法
US20060127320A1 (en) *	2004-05-10	2006-06-15	Nastech Pharmaceutical Company Inc.	Method of delivering parathyroid hormone to a human
US20060052305A1 (en) *	2004-05-10	2006-03-09	Nastech Pharmaceutical Company Inc.	Method of treating osteoporosis using intranasal parathyroid hormone
WO2005115441A2 (en) *	2004-05-10	2005-12-08	Nastech Pharmaceutical Company Inc.	Compositions and methods for enhanced mucosal delivery of parathyroid hormone
US20060189533A1 (en) *	2004-05-10	2006-08-24	Nastech Pharmaceutical Company Inc.	Stable pharmaceutical dosage forms of teriparatide
EP1744683B1 (en)	2004-05-13	2016-03-16	Alza Corporation	Apparatus and method for transdermal delivery of parathyroid hormone agents
US7648965B2 (en)	2004-05-14	2010-01-19	Unigene Laboratories Inc.	Method for fostering bone formation and preservation
US20060069021A1 (en) *	2004-08-13	2006-03-30	Nastech Pharmaceutical Company Inc.	Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs
US8575101B2 (en)	2005-01-06	2013-11-05	Kuros Biosurgery Ag	Supplemented matrices for the repair of bone fractures
WO2006073711A2 (en)	2005-01-06	2006-07-13	Kuros Biosurgery Ag	Use of a matrix comprising a contrast agent in soft tissues
EP1879608A4 (en) *	2005-05-11	2009-11-11	Unigene Lab Inc	METHOD FOR STIMULATING BONE FORMATION AND PRESERVATION
US20070173447A1 (en) *	2005-10-25	2007-07-26	Nastech Pharmaceutical Company Inc.	Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent
AU2006315132A1 (en) *	2005-11-10	2007-05-24	Board Of Control Of Michigan Technological University	Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US20080051332A1 (en) *	2005-11-18	2008-02-28	Nastech Pharmaceutical Company Inc.	Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone
US20080119408A1 (en) *	2006-07-07	2008-05-22	Nastech Pharmaceutical Company Inc.	Pth formulations for intranasal delivery
EP1961765A1 (en) *	2006-12-08	2008-08-27	Zealand Pharma A/S	Truncated PTH peptides with a cyclic conformation
BRPI0810530B8 (pt)	2007-04-13	2021-06-22	Kuros Biosurgery Ag	composição, uso da mesma, biomaterial sintético, seu método de fabricação e kit para formar o mesmo
US20110137243A1 (en) *	2007-09-06	2011-06-09	Abbott Cardiovascular Systems Inc.	Coating On A Balloon Device
WO2009072119A2 (en) *	2007-12-04	2009-06-11	Ben-Gurion University Of The Negev Research And Development Authority	Amphiphilic peptide matrices for treatment of osteoporosis
EP2227263A2 (en)	2007-12-28	2010-09-15	Kuros Biosurgery AG	Pdgf fusion proteins incorporated into fibrin foams
JPWO2011030774A1 (ja)	2009-09-09	2013-02-07	旭化成ファーマ株式会社	１回当たり１００〜２００単位のｐｔｈが週１回投与されることを特徴とする、ｐｔｈ含有骨粗鬆症治療／予防剤
CA2782640A1 (en)	2009-12-07	2011-06-16	Michigan Technological University	Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US9295663B2 (en)	2010-07-14	2016-03-29	Abbott Cardiovascular Systems Inc.	Drug coated balloon with in-situ formed drug containing microspheres
WO2012111852A1 (ja) *	2011-02-17	2012-08-23	帝人ファーマ株式会社	椎体骨折治療剤及びその評価方法
ES2882852T3 (es)	2011-03-16	2021-12-02	Kuros Biosurgery Ag	Formulación farmacéutica para la utilización en la fusión espinal
KR20150116468A (ko)	2011-06-07	2015-10-15	아사히 가세이 파마 가부시키가이샤	고순도 ｐｔｈ 함유 동결 건조 제제 및 그의 제조 방법
US9700485B2 (en)	2013-04-24	2017-07-11	Corning Incorporated	Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
JP6815407B2 (ja)	2016-02-01	2021-01-20	イーライリリーアンドカンパニー	副甲状腺ホルモン−抗ｒａｎｋｌ抗体融合化合物
JP2020506926A (ja) *	2017-02-01	2020-03-05	ザ・ジョンズ・ホプキンス・ユニバーシティ	副甲状腺ホルモンと変性椎間板疾患の再生
US20200289621A1 (en) *	2017-09-22	2020-09-17	Asahi Kasei Pharma Corporation	Teriparatide-containing liquid pharmaceutical composition having excellent stability
CN111447943A (zh)	2018-10-29	2020-07-24	旭化成制药株式会社	以按每周2次的频率给予特立帕肽或其盐为特征的骨质疏松症的预防或治疗方法
JP2022543871A (ja)	2019-08-09	2022-10-14	フラッグシップ・パイオニアリング・イノベーションズ・ブイアイ，エルエルシー	副甲状腺ホルモン受容体（ｐｔｈｒ１）の調節剤
GB2590692A (en) *	2019-12-24	2021-07-07	Corthotec Ltd	Composition for improved bone fracture healing

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4086196A (en)	1975-03-28	1978-04-25	Armour Pharmaceutical Company	Parathyroid hormone
IL78342A (en)	1985-04-04	1991-06-10	Gen Hospital Corp	Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
DE3935738A1 (de)	1989-10-27	1991-05-08	Forssmann Wolf Georg	Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
US5208041A (en)	1991-05-23	1993-05-04	Allelix Biopharmaceuticals Inc.	Essentially pure human parathyroid hormone
CA2126299C (en)	1994-06-20	2000-12-12	Gordon E. Willick	Parathyroid hormone analogues for the treatment of osteoporosis
JPH0873376A (ja) *	1994-09-07	1996-03-19	Asahi Chem Ind Co Ltd	骨粗鬆症治療薬
JPH10511095A (ja) *	1994-12-19	1998-10-27	ベスイスラエルディーコネスメディカルセンターインコーポレイテッド	副甲状腺ホルモン又はその作動薬の低用量継続投与
US5747456A (en) *	1994-12-19	1998-05-05	Beth Israel Deaconess Medical Center	Continuous low-dose administration of parathyroid hormone or its agonist
CA2206657C (en) *	1994-12-22	2009-05-19	Astra Aktiebolag	Therapeutic preparation for inhalation containing parathyroid hormone, pth
JPH08310965A (ja) *	1995-05-16	1996-11-26	Chugai Pharmaceut Co Ltd	骨癒合促進剤
NZ502970A (en) *	1997-09-09	2002-03-01	F	Bone healing and fracture repair by administering bone growth promoter parathyroid hormone related peptide (PTHrP) analogs
ZA9811127B (en)	1997-12-09	2000-07-11	Lilly Co Eli	Stabilized teriparatide solutions.
US20040033950A1 (en)	2000-09-26	2004-02-19	Hock Janet M.	Method of increasing bone toughness and stiffness and reducing fractures
DZ2873A1 (fr)	1998-08-19	2003-12-15	Lilly Co Eli	Procédé pour augmenter la dureté et la rigidité osseuse.
US6907597B1 (en)	2000-10-13	2005-06-14	Ati International Srl	Method and apparatus for constructing an executable program in memory
US6967759B2 (en)	2001-12-31	2005-11-22	Texas Instruments Incorporated	Pulse width modulation sequence generation
JP5796714B2 (ja)	2012-01-13	2015-10-21	株式会社リコー	定着装置及び画像形成装置
EP2949301B1 (en)	2014-05-27	2018-04-18	The Procter and Gamble Company	Absorbent core with curved and straight absorbent material areas

1999
- 1999-08-18 DZ DZ990173A patent/DZ2873A1/xx active
- 1999-08-18 AR ARP990104133A patent/AR033639A1/es unknown
- 1999-08-19 HU HUP1200430 patent/HU1200430D0/hu not_active Application Discontinuation
- 1999-08-19 PT PT15152726T patent/PT2907522T/pt unknown
- 1999-08-19 UA UA2000095457A patent/UA72205C2/ru unknown
- 1999-08-19 EP EP10180447.4A patent/EP2266598B1/en not_active Expired - Lifetime
- 1999-08-19 HU HU0101594A patent/HU230697B1/hu unknown
- 1999-08-19 WO PCT/US1999/018961 patent/WO2000010596A1/en active IP Right Grant
- 1999-08-19 DK DK06027055.0T patent/DK1769804T3/da active
- 1999-08-19 US US09/647,278 patent/US6977077B1/en not_active Expired - Lifetime
- 1999-08-19 PT PT101804474T patent/PT2266598T/pt unknown
- 1999-08-19 PT PT06027055T patent/PT1769804E/pt unknown
- 1999-08-19 PL PL343595A patent/PL201688B1/pl not_active IP Right Cessation
- 1999-08-19 AT AT99942350T patent/ATE231000T1/de not_active IP Right Cessation
- 1999-08-19 CA CA002325371A patent/CA2325371C/en not_active Expired - Lifetime
- 1999-08-19 PE PE1999000839A patent/PE20001089A1/es not_active Application Discontinuation
- 1999-08-19 ES ES10180447.4T patent/ES2621653T3/es not_active Expired - Lifetime
- 1999-08-19 EP EP99942350A patent/EP1059933B1/en not_active Revoked
- 1999-08-19 EP EP15152726.4A patent/EP2907522B1/en not_active Revoked
- 1999-08-19 JP JP2000565916A patent/JP2002523375A/ja active Pending
- 1999-08-19 CN CNB998083534A patent/CN1205997C/zh not_active Expired - Lifetime
- 1999-08-19 MY MYPI99003553A patent/MY129227A/en unknown
- 1999-08-19 CZ CZ20004134A patent/CZ301017B6/cs not_active IP Right Cessation
- 1999-08-19 ES ES15152726.4T patent/ES2549551T3/es not_active Expired - Lifetime
- 1999-08-19 CO CO99052525A patent/CO5130020A1/es unknown
- 1999-08-19 IL IL13882999A patent/IL138829A0/xx unknown
- 1999-08-19 BR BR9909445-2A patent/BR9909445A/pt not_active Application Discontinuation
- 1999-08-19 DK DK15152726.4T patent/DK2907522T3/en active
- 1999-08-19 AU AU55750/99A patent/AU746277B2/en not_active Expired
- 1999-08-19 DK DK10180447.4T patent/DK2266598T3/en active
- 1999-08-19 DE DE15152726.4T patent/DE15152726T1/de active Pending
- 1999-08-19 EA EA200001015A patent/EA003362B1/ru not_active IP Right Cessation
- 1999-08-19 ID IDW20010612A patent/ID29039A/id unknown
- 1999-08-19 ES ES99942350T patent/ES2190244T3/es not_active Expired - Lifetime
- 1999-08-19 ES ES06027055T patent/ES2393200T3/es not_active Expired - Lifetime
- 1999-08-19 TR TR2000/03455T patent/TR200003455T2/xx unknown
- 1999-08-19 KR KR10-2001-7002092A patent/KR100454207B1/ko not_active IP Right Cessation
- 1999-08-19 DE DE69904918T patent/DE69904918T2/de not_active Expired - Lifetime
- 1999-08-19 PT PT99942350T patent/PT1059933E/pt unknown
- 1999-08-19 DK DK99942350T patent/DK1059933T3/da active
- 1999-08-19 NZ NZ507056A patent/NZ507056A/en not_active IP Right Cessation
- 1999-10-26 TW TW088114185A patent/TW576747B/zh not_active IP Right Cessation
2000
- 2000-10-03 IL IL138829A patent/IL138829A/en unknown
- 2000-11-06 HR HR20000755A patent/HRP20000755A2/hr not_active Application Discontinuation
- 2000-11-24 NO NO20005947A patent/NO323984B1/no not_active IP Right Cessation
2001
- 2001-02-14 HK HK01101056A patent/HK1030545A1/xx unknown
2005
- 2005-04-05 US US11/098,894 patent/US7163684B2/en not_active Expired - Lifetime
2007
- 2007-06-11 NO NO20072983A patent/NO20072983L/no not_active Application Discontinuation
- 2007-10-04 HK HK07110798.6A patent/HK1102496A1/xx unknown
2010
- 2010-10-29 JP JP2010244314A patent/JP2011021035A/ja not_active Withdrawn
2012
- 2012-11-14 CY CY20121101096T patent/CY1113343T1/el unknown
2014
- 2014-03-25 JP JP2014061763A patent/JP6177718B2/ja not_active Expired - Lifetime
- 2014-10-03 JP JP2014204577A patent/JP2015028065A/ja not_active Withdrawn
2016
- 2016-01-18 HK HK16100519.4A patent/HK1212602A1/zh not_active IP Right Cessation
2017
- 2017-06-26 JP JP2017124301A patent/JP2017190332A/ja not_active Withdrawn
- 2017-10-13 CY CY20171101077T patent/CY1119552T1/el unknown

Also Published As

Publication number	Publication date
JP2002523375A (ja)	2002-07-30
ATE231000T1 (de)	2003-02-15
PT2266598T (pt)	2017-05-02
KR100454207B1 (ko)	2004-10-26
US6977077B1 (en)	2005-12-20
EP1059933B1 (en)	2003-01-15
UA72205C2 (ru)	2005-02-15
ES2549551T3 (es)	2017-11-27
KR20010072763A (ko)	2001-07-31
EA200001015A1 (ru)	2001-02-26
PE20001089A1 (es)	2000-11-04
CA2325371C (en)	2004-08-17
EP1059933A1 (en)	2000-12-20
IL138829A (en)	2011-01-31
DE69904918D1 (de)	2003-02-20
JP6177718B2 (ja)	2017-08-09
CA2325371A1 (en)	2000-03-02
DK2907522T1 (da)	2015-10-19
EP2266598B1 (en)	2017-02-22
DE15152726T1 (de)	2015-12-10
PT2907522T (pt)	2017-10-23
CY1119552T1 (el)	2018-03-07
DE69904918T2 (de)	2003-11-13
JP2014139220A (ja)	2014-07-31
HU1200430D0 (hu)	2001-11-28
HUP0101594A2 (hu)	2001-11-28
HU230697B1 (hu)	2017-09-28
ES2549551T1 (es)	2015-10-29
HK1030545A1 (en)	2001-05-11
NO20005947L (no)	2000-11-24
DK2907522T3 (en)	2017-10-23
TR200003455T2 (tr)	2001-06-21
CZ301017B6 (cs)	2009-10-14
PT1059933E (pt)	2003-06-30
CN1205997C (zh)	2005-06-15
JP2015028065A (ja)	2015-02-12
NO20072983L (no)	2000-11-24
CZ20004134A3 (cs)	2001-08-15
EP2266598A1 (en)	2010-12-29
NO20005947D0 (no)	2000-11-24
HK1102496A1 (en)	2007-11-23
AU5575099A (en)	2000-03-14
MY129227A (en)	2007-03-30
CO5130020A1 (es)	2002-02-27
US20050197294A1 (en)	2005-09-08
BR9909445A (pt)	2000-12-12
WO2000010596A1 (en)	2000-03-02
NZ507056A (en)	2003-10-31
ES2393200T3 (es)	2012-12-19
US7163684B2 (en)	2007-01-16
ID29039A (id)	2001-07-26
PT1769804E (pt)	2012-11-13
ES2621653T3 (es)	2017-07-04
AU746277B2 (en)	2002-04-18
DK2266598T3 (en)	2017-05-15
EP2907522A1 (en)	2015-08-19
EA003362B1 (ru)	2003-04-24
TW576747B (en)	2004-02-21
HRP20000755A2 (en)	2001-02-28
JP2017190332A (ja)	2017-10-19
DK1059933T3 (da)	2003-04-07
JP2011021035A (ja)	2011-02-03
PL343595A1 (en)	2001-08-27
EP2907522B1 (en)	2017-08-02
IL138829A0 (en)	2001-10-31
CY1113343T1 (el)	2016-06-22
DZ2873A1 (fr)	2003-12-15
HK1212602A1 (zh)	2016-06-17
HUP0101594A3 (en)	2002-01-28
DK1769804T3 (da)	2012-10-15
ES2190244T3 (es)	2003-07-16
NO323984B1 (no)	2007-07-30
CN1308545A (zh)	2001-08-15
AR033639A1 (es)	2004-01-07

Publication	Publication Date	Title
PL201688B1 (pl)	2009-04-30	Zastosowanie hormonu przytarczyc
US7351414B2 (en)	2008-04-01	Method of reducing the risk of bone fracture
US20070270341A1 (en)	2007-11-22	Parathyroid hormone analogues and methods of use
CA2383574A1 (en)	2001-03-29	Method for reducing the risk of cancer
EP1769804B1 (en)	2012-09-19	hPTH(1-34) for use in preventing or reducing the incidence or severity of vertebral and / or non vertebral fracture in a male human
EP1295605A2 (en)	2003-03-26	Method of increasing bone toughness and stiffness and reducing fractures
US20080119819A1 (en)	2008-05-22	Use of Growth Hormone in Treatment of Long-Bone Fractures
MXPA00009982A (en)	2001-07-31	Method of increasing bone toughness and stiffness and reducing fractures

Legal Events

Date	Code	Title	Description
2014-04-30	LAPS	Decisions on the lapse of the protection rights	Effective date: 20120819